home ver. 2.3. site index contact us

Message from the CEO
How We Work
Business Integrity
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Supplier Registration
Diversity Colleague Demographics

Management Biographies

STEVEN H. KOEHLER
Vice President and Controller
Schering-Plough Corporation
Kenilworth, New Jersey

Steven H. Koehler is vice president and controller of Schering-Plough Corporation.

Koehler joined Schering-Plough in March 2006 from The Medicines Company, where until his departure he served as senior vice president, chief financial officer and treasurer.

During his career, Koehler held senior positions in the finance divisions at several pharmaceutical companies. He served as vice president and chief financial officer at Vion Pharmaceuticals. He also was vice president, Finance Americas, for the Knoll Pharmaceuticals Company, the U.S. pharmaceutical unit of BASF. While at BASF, he spent four years as vice president, global finance and controller, based in Germany.

He also had divisional finance lead positions at Baxter International Inc. Koehler, a Certified Public Accountant, began his career in the auditing profession with Arthur Andersen LLP. He holds a B.A. from Duke University, Durham, N.C., and an M.B.A. from Northwestern University, Evanston, IL.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.



Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough